logo
Losing weight in middle age could reduce chronic diseases later, study shows

Losing weight in middle age could reduce chronic diseases later, study shows

CNN10 hours ago

Sign up for CNN's Fitness, But Better newsletter series. Our seven-part guide will help you ease into a healthy routine, backed by experts.
All the work that goes into losing weight in middle age could set you up for a longer, healthier life later, according to a new study.
A sustained weight loss of about 6.5% of body weight without medications or surgery in middle-aged people is linked to substantial long-term health benefits, said lead study author Dr. Timo Strandberg, professor of geriatric medicine at the University of Helsinki in Finland.
Those benefits included a reduction of risk for both chronic diseases and death from all causes.
The study, published Tuesday in the journal JAMA Network Open, analyzed data of about 23,000 people from three different groups across different time periods: one group from 1985 to 1988, another from 1964 to 1973, and a third between 2000 and 2013.
Researchers grouped the people in the studies based on their starting body mass index (BMI) and whether they gained, lost or maintained weight and compared the patterns with hospitalizations and death records.
People who lost weight in midlife were less likely to experience heart attacks, strokes, cancer, asthma or chronic obstructive pulmonary disease in their older years, according to the study.
Those who lost weight were also less likely to have died of any cause over the next 35 years, the study found.
It's important to note that much of the data was collected before weight loss medications or surgeries were widely available, meaning that the benefits largely came from body changes driven by alterations in diet and exercise, Strandberg said.
The study is important because it provides evidence of the relationship between weight loss and both cardiovascular disease and mortality, which hasn't been studied enough, said Dr. Aayush Visaria, a clinical researcher and incoming instructor of medicine at Rutgers Robert Wood Johnson Medical School in New Jersey. He was not involved in the research.
Although the study is strong in that it utilizes a large sample, there are some limitations when applying the results, Visaria said.
The study was conducted on White Europeans, meaning that it's difficult to generalize the results to different populations, Strandberg said.
'BMI is very different across different racial ethnic groups,' Visaria said.
And BMI, which looks at weight in proportion to height, isn't always the most accurate way to gauge body composition, he added. BMI is still used widely because it is easy to calculate, but it doesn't differentiate based on a person's proportion of bone or muscle, Visaria said.
'There's so many variables that might play into how someone's body composition changes, even though maybe their weight might not change as much,' Visaria said.
Other studies suggest that the fat distribution makes a big difference –– the fat around a person's organs may be what really drives a lot of disease risk, he said.
Lifestyle changes –– such as a healthy diet and more exercise –– were important factors in the risk reduction.
The study was observational, meaning that the data can show a relationship between weight loss and a reduction in chronic disease and mortality risk, but researchers can't say for sure that the weight loss was the factor that lowered the risk, Visaria said.
Although the researchers adjusted for other factors that could influence the risk, such as age, they did not adjust for lifestyle behaviors such as diet and physical activity, he added. Those changes could be behind the lowered risk of chronic diseases just as the weight loss itself could be, Visaria said.
Both weight loss and the behavioral changes behind it are often tied together in improving health, Strandberg noted.
Weight loss relieves conditions such as osteoarthritis, obstructive sleep apnea and fatty liver, while changes to diet and exercise have been shown to decrease cardiovascular risks, he added.
Lifestyle is always important when it comes to good health, meaning that you should continue to strive for a healthy diet and good physical activity –– even if you are using weight loss medications, Visaria said.
The Mediterranean diet –– which prioritizes fruits, vegetables, grains, olive oil, and nuts and seeds –– has consistently been ranked the best diet for wellness and disease prevention.
Studies suggest this way of eating may improve bone density in older years, prevent some cancers and lower risk of heart disease.
For physical activity, the World Health Organization recommends that adults engage in at least 150 minutes per week of moderate-intensity or 75 minutes of vigorous-intensity aerobic activity, along with muscle-strengthening activities at least twice a week.
However, obesity is not just a problem individuals need to tackle –– it is a structural issue as well, Strandberg said.
Healthy foods and opportunities for physical activity need to be more accessible in modern societies to help curb the health impacts associated with obesity, he added.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Dassault Systèmes and Patrick Jouin Unveil 'Ta.Tamu,' Their Latest Collaboration Redefining Traditional Design
Dassault Systèmes and Patrick Jouin Unveil 'Ta.Tamu,' Their Latest Collaboration Redefining Traditional Design

Associated Press

timean hour ago

  • Associated Press

Dassault Systèmes and Patrick Jouin Unveil 'Ta.Tamu,' Their Latest Collaboration Redefining Traditional Design

PARIS--(BUSINESS WIRE)--Jun 25, 2025-- Dassault Systèmes (Euronext Paris: FR0014003TT8, and the French designer Patrick Jouin today unveiled ' a lightweight, 3D-printed and functional chair, co-created using the 3DEXPERIENCE platform on the cloud. serves as a proof of concept for emerging, generative design processes that combine AI-powered virtual twins and the frugal use of materials to drive the generative economy. This press release features multimedia. View the full release here: Dassault Systèmes and the French designer Patrick Jouin unveiled ' co-created using the 3DEXPERIENCE platform on the cloud. is the result of a four-year dialogue between Patrick Jouin's intuitive design approach and Dassault Systèmes' 3DEXPERIENCE platform. Designers and engineers redefined how a chair could be conceived — challenging traditional design methods, pushing formal and structural limits, and inventing new ways to minimize matter. Developed through enhanced ideation and concept development, and a life cycle assessment integrated early in the process, pioneering aesthetics were inspired by biomimicry and the structural logic of the human body, such as bone density and joint articulation. The light yet robust lattice structure weighs just 8.6 pounds (3.9 kg), can support 220 pounds (100 kg), and can be 3D printed in a flat, folded position without needing assembly. 'Nature uses only the energy and materials it needs. We wanted to apply this very simple philosophy to the development of With the help of new collaborative technologies of Dassault Systèmes, we are now able to come up with new ideas and make them possible, creating more efficiently while producing less waste, right from the design process,' said Jouin. Collaborating around an AI-powered virtual twin, design teams modeled and simulated the behavior of complex assembled components, using topological optimization to refine every joint, unfolding articulation, and zone of pressure and support. At each stage, the design evolved in real time through close interaction with the 3DEXPERIENCE platform, with changes updated and visible in the virtual twin. Teams modified the chair's geometry while balancing its aesthetics, resulting in an optimal design where gesture, function, and structure converge in a chair that weighs 75% less than it would have weighed at full density. 'To improve the world we live in, we have to change the way we produce, design and use materials. represents a call to action for industry to embrace a generative economy instead of continuing to create without limits,' said Anne Asensio, Vice President Design Experience, Dassault Systèmes. ' was created with the technology used to innovate sustainably in industrial contexts. As a science-based company, we want to create value for society in every aspect of people's lives through our 3DEXPERIENCE platform. Design processes integrating modeling and simulation from the start lead to innovations that improve real life.' ### Through objects such as One Shot, Bloom, and the monolithic bench at the Palais de Tokyo, Patrick Jouin has revealed the ability of these tools to generate intuitive, lightweight, and sometimes otherwise unattainable forms. Since 2019, he has been engaged in an experimental collaboration with Anne Asensio and the teams at Dassault Systèmes, exploring generative design, folding, and deployability. View source version on CONTACT: Dassault Systèmes Press Contacts Corporate / France Arnaud MALHERBE [email protected] +33 (0)1 61 62 87 73North America Natasha LEVANTI [email protected] +1 (508) 449 8097EMEA Virginie BLINDENBERG [email protected] +33 (0) 1 61 62 84 21China Grace MU [email protected] +86 10 6536 2288Japan Reina YAMAGUCHI [email protected] +81 90 9325 2545Korea Jeemin JEONG [email protected] +82 2 3271 6653India Priyanka PANDEY [email protected] +91 9886302179AP South Hazel FOO [email protected] +65 8333 3484Patrick Jouin iD Studio Press Contacts [email protected] [email protected] +33 1 55 28 89 15 KEYWORD: FRANCE EUROPE INDUSTRY KEYWORD: TECHNOLOGY ENGINEERING CHEMICALS/PLASTICS MANUFACTURING APPS/APPLICATIONS CONSTRUCTION & PROPERTY ARTIFICIAL INTELLIGENCE ENVIRONMENT SUSTAINABILITY SOFTWARE OTHER MANUFACTURING ELECTRONIC DESIGN AUTOMATION DATA MANAGEMENT INTERIOR DESIGN SOURCE: Dassault Systèmes Copyright Business Wire 2025. PUB: 06/25/2025 01:00 AM/DISC: 06/25/2025 01:01 AM

Galderma Initiates Two New Clinical Trials Investigating Nemolizumab in Patients With Systemic Sclerosis and Chronic Pruritus of Unknown Origin
Galderma Initiates Two New Clinical Trials Investigating Nemolizumab in Patients With Systemic Sclerosis and Chronic Pruritus of Unknown Origin

Associated Press

timean hour ago

  • Associated Press

Galderma Initiates Two New Clinical Trials Investigating Nemolizumab in Patients With Systemic Sclerosis and Chronic Pruritus of Unknown Origin

ZUG, Switzerland--(BUSINESS WIRE)--Jun 25, 2025-- Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the initiation of two new clinical trials to investigate the efficacy and safety of nemolizumab in treating patients living with Systemic Sclerosis (SSc) and Chronic Pruritus of Unknown Origin (CPUO) – two chronic conditions with high unmet need. 1-3,7 Nemolizumab is a monoclonal antibody that specifically targets the IL-31 receptor alpha, inhibiting the signaling of IL-31, a neuroimmune cytokine that plays a role in driving itch – the main symptom of CPUO – and inflammation and fibrosis, which are hallmarks of SSc. 1,3,4 'Investigating nemolizumab in two new trials in Systemic Sclerosis and Chronic Pruritus of Unknown Origin, both of which are associated with poor patient outcomes and low quality of life, underscores our commitment to addressing skin conditions with high unmet needs. These trials may help us better understand these complex diseases and offer hope for patients seeking relief from these severe and potentially life-threatening conditions.' BALDO SCASSELLATI SFORZOLINI, M.D., PH.D. GLOBAL HEAD OF R&D GALDERMA Systemic Sclerosis (SSc) SSc is a rare, potentially fatal autoimmune disease that causes inflammation and fibrosis (hardening) of the skin and internal organs. 1 It most commonly affects women between the ages of 30 and 50 years old, often leading to a lower quality of life and a much higher risk of death compared to healthy people of the same age. 2,8 Currently, there are no approved therapies that address the disease as a whole, highlighting the urgent need for effective treatments. 1,2,8 Galderma's phase II proof-of-concept study is a multicenter, randomized, double-blind, placebo-controlled study investigating the pharmacokinetics and pharmacodynamics of nemolizumab in adults with SSc. Patient enrollment is planned to begin in H2 2025, with completion anticipated in 2028. This trial represents a significant step towards addressing the remaining unmet treatment needs in SSc and demonstrates Galderma's commitment to driving progress for patients living with this disease. The study was designed in collaboration with a Steering Committee of world-leading rheumatology and dermatology experts, including lead trial investigator, Professor Oliver Distler, M.D., Zürich, Switzerland; Professor Dinesh Khanna, M.D., Director of the Scleroderma Program, University of Michigan, United States (U.S.); Professor Robert Spiera, M.D., Director of the Scleroderma, Vasculitis and Myositis Center, Hospital for Special Surgery, New York, U.S.; and Professor Johann Gudjonsson, M.D., PhD, Dermatologist, University Hospital Michigan, U.S. The trial is expected to be conducted in several countries in North America, Europe and South America. More information about the study will be made available soon on the website. 'Systemic Sclerosis can have a profound impact on both the quality and length of a person's life. It causes the skin to harden, damages blood vessels, leads to joint pain, and can result in serious fibrosis in multiple internal organs, sometimes with life-threatening consequences. With no currently approved treatments that are indicated to treat the several symptoms this autoimmune disease presents, I look forward to investigating the role that nemolizumab could potentially play in this condition.' PROFESSOR OLIVER DISTLER, M.D. LEAD INVESTIGATOR: SYSTEMIC SCLEROSIS PHASE II STUDY ZÜRICH, SWITZERLAND Chronic Pruritus of Unknown Origin (CPUO) CPUO is an underdiagnosed condition defined as itch lasting for more than six weeks without an identified cause and mostly affects the elderly. 3 The chronic and persistent itch is often described as being as debilitating as chronic pain, leading to reduced quality of life and affecting sleep patterns and mood. 3,7 There are currently no approved treatments for this condition. 3 Galderma's new phase II CPUO trial reinforces the company's commitment to exploring options for patients with chronic skin conditions that significantly impact quality of life. This randomized, double-blind, placebo-controlled proof-of-concept study will explore the pharmacokinetics and pharmacodynamics of nemolizumab in adults. Enrollment is expected to start in H2 2025 in the U.S., with completion anticipated in 2026. The study was designed in collaboration with a Steering Committee of world-leading dermatology experts, including the lead investigator Dr. Shawn Kwatra, M.D., PhD., Joseph W. Burnett Endowed Professor, Chairman of Dermatology, University of Maryland School of Medicine, U.S., and Dr. Sarina Elmariah, MD, PhD, MPH, Associate Professor and Dermatology Director at the Center for Itch and Neurosensory Disorders at the University of California in San Francisco, U.S. The study is being conducted in the U.S. and more information about the study will be made available soon on the website. 'It is challenging to treat Chronic Pruritus of Unknown Origin as physicians have limited therapeutic options specifically targeting the underlying cause of itch. With the extensive data showing that IL-31 is a key driver of itch, I'm excited to explore whether nemolizumab's inhibition of IL-31 signaling might effectively reduce the intractable itch experienced by patients with Chronic Pruritus of Unknown Origin.' DOCTOR SHAWN KWATRA, M.D., PHD LEAD INVESTIGATOR, CHRONIC PRURITUS OF UNKNOWN ORIGIN PHASE II STUDY JOSEPH W. BURNETT ENDOWED PROFESSOR CHAIRMAN OF DERMATOLOGY, UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE, U.S. About nemolizumab Nemolizumab was approved in August 2024 by the U.S. Food and Drug Administration (U.S. FDA) for the treatment of adults with prurigo nodularis. 5 In December 2024, it was also approved by the U.S. FDA for the treatment of patients 12 years and older with moderate-to-severe atopic dermatitis, in combination with topical corticosteroids and/or calcineurin inhibitors when the disease is not adequately controlled with topical prescription therapies. 5 To date, nemolizumab is approved for both moderate-to-severe atopic dermatitis and prurigo nodularis by multiple regulatory authorities around the world, including in the European Union, Australia, Singapore, Switzerland and the United Kingdom. Additional regulatory submissions and reviews are ongoing. Nemolizumab was initially developed by Chugai Pharmaceutical Co., Ltd. In 2016, Galderma obtained exclusive rights to the development and marketing of nemolizumab worldwide, except in Japan. In Japan, nemolizumab is marketed as Mitchga ® and is approved for the treatment of prurigo nodularis, as well as pruritus associated with atopic dermatitis in pediatric, adolescent, and adult patients. 9,10 About Galderma Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body's largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: . References 1. Jimenez SA, Mendoza FA, Piera-Velasquez S. A review of recent studies on the pathogenesis of Systemic Sclerosis: focus on fibrosis pathways. Front Immunol . 2025;16: 1551911. doi: 10.3389/fimmu.2025.1551911 2. Truchetet ME, et al. Current Concepts on the Pathogenesis of Systemic Sclerosis. Clin Rev Allergy Immunol . 2021;64(3): 262–283. doi: 10.1007/s12016-021-08889-8 3. Teresa J, et al. Therapeutics in chronic pruritus of unknown origin. Itch . 2023;8(1): pe64. doi: 10.1097/itx.0000000000000064 4. Silverberg JI, et al. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. J Allergy Clin Immunol . 2020;145(1): 173-182. doi: 10.1016/ 5. Nemluvio ® U.S. Prescribing Information. Available online . Accessed June 2025 6. Nemluvio ® European Medicines Agency. Summary of Product Characteristics. Available online . Accessed June 2025 7. Andrade E, et al. Interventions for chronic pruritus of unknown origin. CDSR . 2020;1(1): CD013128. doi: 10.1002/ 8. Scleroderma & Systemic Sclerosis. National Health Service. Available online . Accessed June 2025 9. Chugai Pharmaceutical Co., Ltd. Maruho Obtained Regulatory Approval for Mitchga, the first Antibody Targeting IL-31 for Itching Associated with Atopic Dermatitis. Available online . Accessed June 2025 10. Chugai Pharmaceutical Co., Ltd. Mitchga Approved for Itching in Pediatric Atopic Dermatitis and Prurigo Nodularis, for its Subcutaneous Injection 30mg Vials. Available online . Accessed June 2025 View source version on CONTACT: For further information: Christian Marcoux, Chief Communications Officer [email protected] +41 76 315 26 50 Richard Harbinson Corporate Communications Director [email protected] +41 76 210 60 62 Céline Buguet Franchises and R&D Communications Director [email protected] +41 76 249 90 87 Emil Ivanov Head of Strategy, Investor Relations, and ESG [email protected] +41 21 642 78 12 Jessica Cohen Investor Relations and Strategy Director [email protected] +41 21 642 76 43 KEYWORD: SWITZERLAND EUROPE INDUSTRY KEYWORD: HEALTH OTHER HEALTH CLINICAL TRIALS RESEARCH SCIENCE PHARMACEUTICAL BIOTECHNOLOGY SOURCE: Galderma Copyright Business Wire 2025. PUB: 06/25/2025 01:00 AM/DISC: 06/25/2025 01:01 AM

Galderma Initiates Two New Clinical Trials Investigating Nemolizumab in Patients With Systemic Sclerosis and Chronic Pruritus of Unknown Origin
Galderma Initiates Two New Clinical Trials Investigating Nemolizumab in Patients With Systemic Sclerosis and Chronic Pruritus of Unknown Origin

Yahoo

timean hour ago

  • Yahoo

Galderma Initiates Two New Clinical Trials Investigating Nemolizumab in Patients With Systemic Sclerosis and Chronic Pruritus of Unknown Origin

Systemic Sclerosis (SSc) is a life-threatening autoimmune disease that causes severe inflammation and fibrosis, while Chronic Pruritus of Unknown Origin (CPUO) is characterized by a persistent, chronic itch with an unknown cause1-3 Nemolizumab is the first approved monoclonal antibody that specifically targets the IL-31 receptor alpha, inhibiting the signaling of IL-31. It is approved for the treatment of moderate-to-severe atopic dermatitis and prurigo nodularis by multiple regulatory authorities around the world4-6 IL-31 is a neuroimmune cytokine that is involved in inflammation and fibrosis – both hallmarks of SSc – and drives itch, a key symptom of CPUO1,3,4 Enrollment for Galderma's phase II studies of nemolizumab is planned to begin in H2 2025 ZUG, Switzerland, June 25, 2025--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the initiation of two new clinical trials to investigate the efficacy and safety of nemolizumab in treating patients living with Systemic Sclerosis (SSc) and Chronic Pruritus of Unknown Origin (CPUO) – two chronic conditions with high unmet need.1-3,7 Nemolizumab is a monoclonal antibody that specifically targets the IL-31 receptor alpha, inhibiting the signaling of IL-31, a neuroimmune cytokine that plays a role in driving itch – the main symptom of CPUO – and inflammation and fibrosis, which are hallmarks of SSc.1,3,4 "Investigating nemolizumab in two new trials in Systemic Sclerosis and Chronic Pruritus of Unknown Origin, both of which are associated with poor patient outcomes and low quality of life, underscores our commitment to addressing skin conditions with high unmet needs. These trials may help us better understand these complex diseases and offer hope for patients seeking relief from these severe and potentially life-threatening conditions."BALDO SCASSELLATI SFORZOLINI, M.D., PH.D. GLOBAL HEAD OF R&D GALDERMA Systemic Sclerosis (SSc) SSc is a rare, potentially fatal autoimmune disease that causes inflammation and fibrosis (hardening) of the skin and internal organs.1 It most commonly affects women between the ages of 30 and 50 years old, often leading to a lower quality of life and a much higher risk of death compared to healthy people of the same age.2,8 Currently, there are no approved therapies that address the disease as a whole, highlighting the urgent need for effective treatments.1,2,8 Galderma's phase II proof-of-concept study is a multicenter, randomized, double-blind, placebo-controlled study investigating the pharmacokinetics and pharmacodynamics of nemolizumab in adults with SSc. Patient enrollment is planned to begin in H2 2025, with completion anticipated in 2028. This trial represents a significant step towards addressing the remaining unmet treatment needs in SSc and demonstrates Galderma's commitment to driving progress for patients living with this disease. The study was designed in collaboration with a Steering Committee of world-leading rheumatology and dermatology experts, including lead trial investigator, Professor Oliver Distler, M.D., Zürich, Switzerland; Professor Dinesh Khanna, M.D., Director of the Scleroderma Program, University of Michigan, United States (U.S.); Professor Robert Spiera, M.D., Director of the Scleroderma, Vasculitis and Myositis Center, Hospital for Special Surgery, New York, U.S.; and Professor Johann Gudjonsson, M.D., PhD, Dermatologist, University Hospital Michigan, U.S. The trial is expected to be conducted in several countries in North America, Europe and South America. More information about the study will be made available soon on the website. "Systemic Sclerosis can have a profound impact on both the quality and length of a person's life. It causes the skin to harden, damages blood vessels, leads to joint pain, and can result in serious fibrosis in multiple internal organs, sometimes with life-threatening consequences. With no currently approved treatments that are indicated to treat the several symptoms this autoimmune disease presents, I look forward to investigating the role that nemolizumab could potentially play in this condition."PROFESSOR OLIVER DISTLER, M.D. LEAD INVESTIGATOR: SYSTEMIC SCLEROSIS PHASE II STUDY ZÜRICH, SWITZERLAND Chronic Pruritus of Unknown Origin (CPUO) CPUO is an underdiagnosed condition defined as itch lasting for more than six weeks without an identified cause and mostly affects the elderly.3 The chronic and persistent itch is often described as being as debilitating as chronic pain, leading to reduced quality of life and affecting sleep patterns and mood.3,7 There are currently no approved treatments for this condition.3 Galderma's new phase II CPUO trial reinforces the company's commitment to exploring options for patients with chronic skin conditions that significantly impact quality of life. This randomized, double-blind, placebo-controlled proof-of-concept study will explore the pharmacokinetics and pharmacodynamics of nemolizumab in adults. Enrollment is expected to start in H2 2025 in the U.S., with completion anticipated in 2026. The study was designed in collaboration with a Steering Committee of world-leading dermatology experts, including the lead investigator Dr. Shawn Kwatra, M.D., PhD., Joseph W. Burnett Endowed Professor, Chairman of Dermatology, University of Maryland School of Medicine, U.S., and Dr. Sarina Elmariah, MD, PhD, MPH, Associate Professor and Dermatology Director at the Center for Itch and Neurosensory Disorders at the University of California in San Francisco, U.S. The study is being conducted in the U.S. and more information about the study will be made available soon on the website. "It is challenging to treat Chronic Pruritus of Unknown Origin as physicians have limited therapeutic options specifically targeting the underlying cause of itch. With the extensive data showing that IL-31 is a key driver of itch, I'm excited to explore whether nemolizumab's inhibition of IL-31 signaling might effectively reduce the intractable itch experienced by patients with Chronic Pruritus of Unknown Origin."DOCTOR SHAWN KWATRA, M.D., PHD LEAD INVESTIGATOR, CHRONIC PRURITUS OF UNKNOWN ORIGIN PHASE II STUDY JOSEPH W. BURNETT ENDOWED PROFESSOR CHAIRMAN OF DERMATOLOGY, UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE, U.S. About nemolizumab Nemolizumab was approved in August 2024 by the U.S. Food and Drug Administration (U.S. FDA) for the treatment of adults with prurigo nodularis.5 In December 2024, it was also approved by the U.S. FDA for the treatment of patients 12 years and older with moderate-to-severe atopic dermatitis, in combination with topical corticosteroids and/or calcineurin inhibitors when the disease is not adequately controlled with topical prescription therapies.5 To date, nemolizumab is approved for both moderate-to-severe atopic dermatitis and prurigo nodularis by multiple regulatory authorities around the world, including in the European Union, Australia, Singapore, Switzerland and the United Kingdom. Additional regulatory submissions and reviews are ongoing. Nemolizumab was initially developed by Chugai Pharmaceutical Co., Ltd. In 2016, Galderma obtained exclusive rights to the development and marketing of nemolizumab worldwide, except in Japan. In Japan, nemolizumab is marketed as Mitchga® and is approved for the treatment of prurigo nodularis, as well as pruritus associated with atopic dermatitis in pediatric, adolescent, and adult patients.9,10 About Galderma Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body's largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: References 1. Jimenez SA, Mendoza FA, Piera-Velasquez S. A review of recent studies on the pathogenesis of Systemic Sclerosis: focus on fibrosis pathways. Front Immunol. 2025;16: 1551911. doi: 10.3389/fimmu.2025.1551911 2. Truchetet ME, et al. Current Concepts on the Pathogenesis of Systemic Sclerosis. Clin Rev Allergy Immunol. 2021;64(3): 262–283. doi: 10.1007/s12016-021-08889-8 3. Teresa J, et al. Therapeutics in chronic pruritus of unknown origin. Itch. 2023;8(1): pe64. doi: 10.1097/itx.0000000000000064 4. Silverberg JI, et al. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. J Allergy Clin Immunol. 2020;145(1): 173-182. doi: 10.1016/ 5. Nemluvio® U.S. Prescribing Information. Available online. Accessed June 2025 6. Nemluvio® European Medicines Agency. Summary of Product Characteristics. Available online. Accessed June 2025 7. Andrade E, et al. Interventions for chronic pruritus of unknown origin. CDSR. 2020;1(1): CD013128. doi: 10.1002/ 8. Scleroderma & Systemic Sclerosis. National Health Service. Available online. Accessed June 2025 9. Chugai Pharmaceutical Co., Ltd. Maruho Obtained Regulatory Approval for Mitchga, the first Antibody Targeting IL-31 for Itching Associated with Atopic Dermatitis. Available online. Accessed June 2025 10. Chugai Pharmaceutical Co., Ltd. Mitchga Approved for Itching in Pediatric Atopic Dermatitis and Prurigo Nodularis, for its Subcutaneous Injection 30mg Vials. Available online. Accessed June 2025 View source version on Contacts For further information:Christian Marcoux, Communications +41 76 315 26 50Richard HarbinsonCorporate Communications +41 76 210 60 62Céline BuguetFranchises and R&D Communications +41 76 249 90 87Emil IvanovHead of Strategy, Investor Relations, and +41 21 642 78 12Jessica CohenInvestor Relations and Strategy +41 21 642 76 43 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store